AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32238921 — intervention group
Group type: EXPERIMENTAL
Intervention: MRX34 treatment with dexamethasone premedication
Number of subjects: 85
Study 32238921 — intervention group
Group type: EXPERIMENTAL
Intervention: MRX34
Number of subjects: 85
Study 32239137 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 149
Study 32239319 — intervention group
Group type: EXPERIMENTAL
Intervention: Low FVC participants
Number of subjects: 0
Study 32239319 — intervention group
Group type: COMPARATOR
Intervention: Normal spirometry participants
Number of subjects: 0
Study 32239476 — intervention group
Group type: EXPERIMENTAL
Intervention: r-hGH delivered with Easypod™
Number of subjects: 147
Study 32239971 — intervention group
Group type: EXPERIMENTAL
Intervention: e-Device (ava®) for self-injection of certolizumab pegol (CZP)
Number of subjects: 67
Study 32240454 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab SC administered at home by a healthcare professional (HCP)
Number of subjects: 102
Study 32240454 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab SC administered at home
Number of subjects: 102
Study 32240629 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly rifapentine (900 mg) plus isoniazid (900 mg) for 12 weeks
Number of subjects: 61
Study 32240629 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir (50 mg daily) for 8 weeks prior to rifapentine-isoniazid
Number of subjects: 61
Study 32240629 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events (grade 3 or higher)
Number of subjects: 61
Study 32240629 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV viral loads measured at baseline and at weeks 11 and 24
Number of subjects: 61
Study 32240793 — intervention group
Group type: EXPERIMENTAL
Intervention: CC-90010 (45 mg, 4 days on/24 days off)
Number of subjects: 69
Study 32240793 — intervention group
Group type: EXPERIMENTAL
Intervention: CC-90010 (various doses)
Number of subjects: 69
Study 32240796 — intervention group
Group type: EXPERIMENTAL
Intervention: Capmatinib 400 mg (tablets) or 600 mg (capsules) b.i.d.
Number of subjects: 55
Study 32240908 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECT/CT-guided elective nodal irradiation (ENI)
Number of subjects: 50
Study 32240908 — intervention group
Group type: COMPARATOR
Intervention: Bilateral elective nodal irradiation (B-ENI)
Number of subjects: 50
Study 32241310 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HT4 receptor agonists
Number of subjects: 0
Study 32241317 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation for end of life factors (knowledge of dementia, social support, feeling supported by healthcare providers, formalized end of life documents, end-of-life discussions)
Number of subjects: 150
Study 32241317 — intervention group
Group type: EXPERIMENTAL
Intervention: MMCGI-SF subscales
Number of subjects: 150
Study 32241330 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with depression
Number of subjects: 419
Study 32241330 — intervention group
Group type: COMPARATOR
Intervention: Women without depression
Number of subjects: 419
Study 32241548 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen therapy (HFNO)
Number of subjects: 60
Study 32241904 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiota from patients with ESRD transplanted to renal injured germ-free mice or antibiotic-treated rats
Number of subjects: 223
Study 32241904 — intervention group
Group type: COMPARATOR
Intervention: Microbiota from healthy controls
Number of subjects: 223
Study 32242035 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity extracorporeal low energy shock wave therapy (LiESWT)
Number of subjects: 50
Study 32242358 — intervention group
Group type: EXPERIMENTAL
Intervention: KTE-X19 CAR T-cell therapy
Number of subjects: 74
Study 32242498 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment
Number of subjects: 0
Study 32242768 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular Lithotripsy
Number of subjects: 0
Study 32243379 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy intervention group receiving 2 sessions of moxibustion in the Heart meridian and Lung meridian.
Number of subjects: 120
Study 32243379 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group and chronic stable angina pectoris group.
Number of subjects: 120
Study 32243941 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 489
Study 32243960 — intervention group
Group type: EXPERIMENTAL
Intervention: NS5A-containing DAA therapy
Number of subjects: 642
Study 32244368 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban
Number of subjects: 42
Study 32244368 — intervention group
Group type: COMPARATOR
Intervention: Increased dose of unfractionated heparin (UFH)
Number of subjects: 42
Study 32245397 — intervention group
Group type: EXPERIMENTAL
Intervention: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir (3D) ± Ribavirin for 12 or 24 weeks
Number of subjects: 39
Study 32245397 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 39
Study 32245502 — intervention group
Group type: EXPERIMENTAL
Intervention: Bispecific CAR T cell therapy targeting CD19 and CD22
Number of subjects: 6
Study 32245906 — intervention group
Group type: EXPERIMENTAL
Intervention: PAN-PROMISE scale (patient-reported outcome measure)
Number of subjects: 524
Study 32245906 — intervention group
Group type: EXPERIMENTAL
Intervention: PAN-PROMISE scale
Number of subjects: 524
Study 32246266 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon-expandable valve (BEV; Sapien 3)
Number of subjects: 56
Study 32246968 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tacrolimus for atopic dermatitis (used for ≥6 weeks)
Number of subjects: 7954
Study 32246968 — intervention group
Group type: COMPARATOR
Intervention: Matched background data from national cancer registries
Number of subjects: 7954
Study 32247041 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent human papillomavirus (qHPV) vaccine
Number of subjects: 0
Study 32247206 — intervention group
Group type: EXPERIMENTAL
Intervention: Extreme hypofractionated doses of 35 Gy in 5 weekly fractions to the whole prostate gland with an integrated boost up to 50 Gy to the mpMRI-defined tumour(s)
Number of subjects: 100
Study 32248659 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (UST) 90 mg subcutaneously at baseline and at weeks 4, 12, 20, 28, 36, and 44, combined with a 24-week prednisone taper.
Number of subjects: 13
Study 32248659 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (UST) with 24 weeks of prednisone.
Number of subjects: 13
Study 32248659 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative definition of prednisone-free remission (not requiring ESR/CRP normalization).
Number of subjects: 13
Study 32248819 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous mitral commissurotomy (PMC)
Number of subjects: 40
Study 32249038 — intervention group
Group type: EXPERIMENTAL
Intervention: PRIMA wireless photovoltaic retinal implant
Number of subjects: 5
Study 32249039 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model incorporating age, sex, BMI, CTX-II, and KL-grade
Number of subjects: 1255
Study 32249039 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative KL-grade between knees of 5, 6, or 7
Number of subjects: 1255
Study 32249039 — intervention group
Group type: EXPERIMENTAL
Intervention: Age (per 5 years)
Number of subjects: 1255
Study 32249039 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline u-CTX-II
Number of subjects: 1255
Study 32249039 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite model (age, sex, BMI, u-CTX-II, KL-grade)
Number of subjects: 1255
Study 32249045 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar drain placement
Number of subjects: 100
Study 32249139 — intervention group
Group type: COMPARATOR
Intervention: Metabolically healthy obese subjects
Number of subjects: 3325
Study 32249139 — intervention group
Group type: COMPARATOR
Intervention: Metabolically unhealthy subjects (regardless of obesity status)
Number of subjects: 3325
Study 32249139 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic unhealthiness
Number of subjects: 3325
Study 32249139 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 3325
Study 32249139 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic unhealthiness in nonobese subjects
Number of subjects: 3325
Study 32249170 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-Coated Balloon (DCB)
Number of subjects: 327
Study 32249170 — intervention group
Group type: COMPARATOR
Intervention: Non-Drug-Coated Balloon (non-DCB)
Number of subjects: 327
Study 32249171 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescribing hormonal contraception
Number of subjects: 25
Study 32249171 — intervention group
Group type: EXPERIMENTAL
Intervention: Training needs, reimbursement, and liability
Number of subjects: 25
Study 32249171 — intervention group
Group type: EXPERIMENTAL
Intervention: Availability of private areas, pharmacists' role as knowledgeable health care team members, and pharmacist accessibility without appointments
Number of subjects: 25
Study 32249171 — intervention group
Group type: EXPERIMENTAL
Intervention: Over-the-counter access to hormonal contraception
Number of subjects: 25
Study 32249171 — intervention group
Group type: EXPERIMENTAL
Intervention: Certification to prescribe and place subdermal contraceptive implants
Number of subjects: 25
Study 32250312 — intervention group
Group type: EXPERIMENTAL
Intervention: UniQure AMT-130
Number of subjects: 0
Study 32250312 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurocrine Biosciences KINECT-HD
Number of subjects: 0
Study 32250517 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib 500 mg single-agent
Number of subjects: 22
Study 32250561 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates exercise
Number of subjects: 30
Study 32251060 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous tocilizumab (TCZ) 162 mg/wk in combination with csDMARDs for 24 weeks
Number of subjects: 284
Study 32251060 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous tocilizumab (TCZ) monotherapy continued until week 52 for patients who achieved remission at week 24
Number of subjects: 284
Study 32251060 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy with csDMARDs
Number of subjects: 284
Study 32251060 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events during follow-up
Number of subjects: 284
Study 32251621 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 10 mg/kg intravenously every 2 weeks (Cohort 1: PD-L1 expression at least 1%)
Number of subjects: 42
Study 32251621 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 10 mg/kg intravenously every 2 weeks (Cohort 2: PD-L1 less than 1% or unevaluable)
Number of subjects: 42
Study 32251621 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-related adverse events
Number of subjects: 42
Study 32251757 — intervention group
Group type: EXPERIMENTAL
Intervention: Parametric Response Mapping (PRM) using coregistered PET and DCE CT imaging
Number of subjects: 21
Study 32251757 — intervention group
Group type: COMPARATOR
Intervention: Concurrent chemoradiation therapy
Number of subjects: 21
Study 32252538 — intervention group
Group type: EXPERIMENTAL
Intervention: Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) - 50 iTBS sessions, 1,800 pulses per session, delivered as 10 daily sessions over 5 consecutive days at 90% resting motor threshold.
Number of subjects: 22
Study 32252538 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological testing before and after SAINT.
Number of subjects: 22
Study 32252696 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified method of scoring the Core Conflictual Relationship Theme (CCRT) based on live semi-structured dynamic interviews without transcribing material.
Number of subjects: 52
Study 32252720 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) treatment for CUD, duration: 90 days, targeted at the left dorsolateral prefrontal cortex.
Number of subjects: 87
Study 32252720 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) treatment for CUD.
Number of subjects: 87
Study 32252720 — intervention group
Group type: COMPARATOR
Intervention: Wait-list group (n=10) as a comparison.
Number of subjects: 87
Study 32252752 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for SBO
Number of subjects: 402
Study 32252781 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (modern radiotherapy techniques: intensity-modulated or volumetric modulated arc radiotherapy)
Number of subjects: 161
Study 32252781 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy alone or in combination with chemotherapy
Number of subjects: 161
Study 32252781 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant treatment (radiotherapy or chemotherapy)
Number of subjects: 161
Study 32252781 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Number of subjects: 161
Study 32252809 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-regulated gene score (IRG-S) in JDM patients
Number of subjects: 57
Study 32252809 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-regulated gene score (IRG-S) in anti-MDA5 autoantibody-positive JDM patients
Number of subjects: 57
Study 32252809 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual gene contributions to IRG-S
Number of subjects: 57
Study 32252809 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of IRG-S with disease activity measures
Number of subjects: 57
Study 32252809 — intervention group
Group type: COMPARATOR
Intervention: Comparison of IRG-S between JDM and CANDLE/SAVI
Number of subjects: 57
Study 32253717 — intervention group
Group type: EXPERIMENTAL
Intervention: Conivaptan (20 mg) administered every 12 hours for 2 days along with standard ICH management
Number of subjects: 7
Study 32253717 — intervention group
Group type: COMPARATOR
Intervention: Standard ICH management
Number of subjects: 7
Study 32254044 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable device intervention with personalized goal-setting and financial incentives
Number of subjects: 99
Study 32254044 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 99
Study 32256049 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab 1 mg/kg, 3 mg/kg, 6 mg/kg, and 10 mg/kg every 2 weeks (dose-escalation phase)
Number of subjects: 49
Study 32256049 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab 200 mg or 600 mg every 4 weeks (dose-expansion phase)
Number of subjects: 49
Study 32256049 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab (all doses)
Number of subjects: 49
Study 32256115 — intervention group
Group type: EXPERIMENTAL
Intervention: Acalabrutinib monotherapy
Number of subjects: 0
Study 32256115 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of acalabrutinib and obinutuzumab
Number of subjects: 0
Study 32256115 — intervention group
Group type: COMPARATOR
Intervention: Acalabrutinib
Number of subjects: 0
Study 32256270 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg caffeine plus 200 mg chlorogenic acid (CFCA)
Number of subjects: 26
Study 32256270 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg caffeine plus 200 mg placebo (starch) (CFPL)
Number of subjects: 26
Study 32256270 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg chlorogenic acid plus 200 mg placebo (CAPL)
Number of subjects: 26
Study 32256270 — intervention group
Group type: COMPARATOR
Intervention: 200 mg placebo plus 200 mg placebo (PLPL)
Number of subjects: 26
Study 32256610 — intervention group
Group type: EXPERIMENTAL
Intervention: Deciduous dental pulp stem cells (DDPSC) associated with hydroxyapatite-collagen sponge (Bio-Oss Collagen® 250 mg, Geistlich)
Number of subjects: 6
Study 32256610 — intervention group
Group type: COMPARATOR
Intervention: rhBMP-2
Number of subjects: 6
Study 32256610 — intervention group
Group type: COMPARATOR
Intervention: iliac crest bone graft
Number of subjects: 6
Study 32256673 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher serum choline levels (T3)
Number of subjects: 866
Study 32256673 — intervention group
Group type: COMPARATOR
Intervention: Serum betaine levels
Number of subjects: 866
Study 32256757 — intervention group
Group type: EXPERIMENTAL
Intervention: Uniblocker
Number of subjects: 60
Study 32256757 — intervention group
Group type: COMPARATOR
Intervention: Left-sided double-lumen tube (LDLT)
Number of subjects: 60
Study 32258217 — intervention group
Group type: EXPERIMENTAL
Intervention: rAAV-DJ-S269T
Number of subjects: 0
Study 32258217 — intervention group
Group type: EXPERIMENTAL
Intervention: rAAV-LK03-Y705+731F
Number of subjects: 0
Study 32258217 — intervention group
Group type: COMPARATOR
Intervention: rAAV-DJ
Number of subjects: 0
Study 32258217 — intervention group
Group type: COMPARATOR
Intervention: rAAV-LK03
Number of subjects: 0
Study 32258361 — intervention group
Group type: EXPERIMENTAL
Intervention: Large scaffold diameter (LScD, ≥3 mm)
Number of subjects: 1785
Study 32258361 — intervention group
Group type: COMPARATOR
Intervention: Small scaffold diameter (SScD, 2.5 mm)
Number of subjects: 1785
Study 32258443 — intervention group
Group type: EXPERIMENTAL
Intervention: Pencil Beam Scanning (PBS)
Number of subjects: 304
Study 32258443 — intervention group
Group type: COMPARATOR
Intervention: Passive Scatter/Uniform Scanning (PS/US)
Number of subjects: 304
Study 32258591 — intervention group
Group type: EXPERIMENTAL
Intervention: Oculomotor and gaze stability exercises applied at home twice a day for three weeks
Number of subjects: 0
Study 32258591 — intervention group
Group type: COMPARATOR
Intervention: Current rehabilitation program
Number of subjects: 0
Study 32258819 — intervention group
Group type: EXPERIMENTAL
Intervention: Covariate-constrained randomization algorithm applied in waves (2-8 facilities/wave) from June 2017 to March 2019.
Number of subjects: 424
Study 32258819 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm 2 allocated more nursing homes with severely cognitive impaired residents above the median.
Number of subjects: 424
Study 32258819 — intervention group
Group type: EXPERIMENTAL
Intervention: Covariate-constrained randomization algorithm.
Number of subjects: 424
Study 32258819 — intervention group
Group type: EXPERIMENTAL
Intervention: Original randomization scheme for TRAIN-AD.
Number of subjects: 424
Study 32258956 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (200 mg testosterone enanthate weekly)
Number of subjects: 50
Study 32258956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 32258987 — intervention group
Group type: EXPERIMENTAL
Intervention: List-based method for measuring food group indicators (FGIs)
Number of subjects: 0
Study 32258987 — intervention group
Group type: COMPARATOR
Intervention: Open recall method for measuring food group indicators (FGIs)
Number of subjects: 0
Study 32258995 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised CACFP meal patterns
Number of subjects: 0
Study 32258996 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher intervention-only programs
Number of subjects: 9
Study 32258996 — intervention group
Group type: COMPARATOR
Intervention: Teacher and classroom training programs
Number of subjects: 9
Study 32259077 — intervention group
Group type: EXPERIMENTAL
Intervention: Ralaniten (EPI-002)
Number of subjects: 0
Study 32259077 — intervention group
Group type: EXPERIMENTAL
Intervention: EPI-045 (analogue of ralaniten)
Number of subjects: 0
Study 32259077 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucuronidated metabolites of ralaniten
Number of subjects: 0
Study 32259257 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk ECG score
Number of subjects: 7362
Study 32259257 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk ECG score
Number of subjects: 7362
Study 32259257 — intervention group
Group type: COMPARATOR
Intervention: ECG markers added to clinical risk factor model
Number of subjects: 7362
Study 32259334 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 81-8973 (Kovaltry) prophylaxis, infused ≥3×/wk (59% of patients)
Number of subjects: 160
Study 32259334 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 81-8973 (Kovaltry) prophylaxis
Number of subjects: 160
Study 32259825 — intervention group
Group type: EXPERIMENTAL
Intervention: AD8 (Ascertain Dementia 8)
Number of subjects: 75
Study 32259825 — intervention group
Group type: COMPARATOR
Intervention: CDR (Clinical Dementia Rating Scale)
Number of subjects: 75
Study 32264716 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-lead Optimizer system
Number of subjects: 60
Study 32264716 — intervention group
Group type: COMPARATOR
Intervention: 3-lead Optimizer system
Number of subjects: 60
Study 32264715 — intervention group
Group type: EXPERIMENTAL
Intervention: iVAS therapy
Number of subjects: 47
Study 32264726 — intervention group
Group type: EXPERIMENTAL
Intervention: FF-10501-01 (IMPDH inhibitor)
Number of subjects: 38
Study 32264845 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 67
Study 32264845 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 67
Study 32264845 — intervention group
Group type: COMPARATOR
Intervention: Implicit measures (not specified)
Number of subjects: 67
Study 32264848 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol marketing exposure
Number of subjects: 720
Study 32264848 — intervention group
Group type: EXPERIMENTAL
Intervention: Demarketing intervention
Number of subjects: 720
Study 32264969 — intervention group
Group type: EXPERIMENTAL
Intervention: Opportunistic infections (OI)
Number of subjects: 572
Study 32264969 — intervention group
Group type: COMPARATOR
Intervention: Serious/severe/very severe non-OI
Number of subjects: 572
Study 32264969 — intervention group
Group type: EXPERIMENTAL
Intervention: Total infections adjudicated
Number of subjects: 572
Study 32265584 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine and dexmedetomidine (group D)
Number of subjects: 52
Study 32265584 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine and magnesium sulfate (group M)
Number of subjects: 52
Study 32265627 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of autologous bone marrow mononuclear cells (BMMCs)
Number of subjects: 22
Study 32265627 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 22
Study 32266070 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion regulation group skills training
Number of subjects: 29